Stevenson Ward

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Part of Novartis AG, Sandoz Ltd. is a British company that develops, produces and markets medicines. The company is based in Camberley, UK and was founded in 1981.

Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA.

Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ.

Acacia Pharma Ltd. develops supportive care product opportunities for post-surgical and cancer patients. It specializes in the discovery and development of cancer supportive care product opportunities based on established drugs. The firm’s product pipeline addresses supportive care indications, such as post-operative and chemotherapy-induced nausea and vomiting, xerostomia and cachexia. The company was founded by Andrew Muncey, Julian Clive Gilbert and Robert William Gristwood in 2006 and is headquartered in Cambridge, the United Kingdom.

Micreos BV develops phage-based products against specific dangerous bacteria. It offers human health, food safety, agriculture and animal health products. The company was founded by Mark Offerhaus and is headquartered in Wageningen, the Netherlands.

NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark.

Ethypharm SAS is a holding company, which engages in developing pharmaceutical products. It offers treatment for pain and addiction, as well as complex generic drugs. The company was founded by G?rard Leduc and Patrice Debregreas in 1977 and is headquartered in Saint-Cloud, France.

May & Baker Ltd. manufactures pharmaceutical products. The company is headquartered in Guildford, GB.

Thrombolytic Science International LLC operates as a vascular medicine and biotech company. The company was founded by Alexis Wallace and Victor Gurewich and is headquartered in Cambridge, MA.

Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands.

MRM Health NV is a biopharmaceutical company, which engages in the discovery and development of therapeutics based on the human microbiome. It offers Simulator of the Human Intestinal Microbial Ecosystem (SHIME), allowing to model the complete intestine and its microbiome in the lab, in both health and disease. The company was founded by Sam Possemiers and is headquartered in Ghent, Belgium.

Third Pole, Inc. engages in the development of cardiopulmonary therapies. Its product is capable of generating nitric oxide from air and electricity. The company is headquartered in San Francisco, CA.

StemCyte, Inc. operates as a biotechnology company that collects, banks and distributes cord blood stem cell transfusion units. It focuses on stem cell transplantation, therapy, applications, diagnostics, and genomic research. The firm uses insulated containers to keep your baby's cord blood cool throughout transport. The company was founded by Denis Rodgerson and Robert Chow in 1997 and is headquartered in Covina, CA.

Universal Voltronics Corp. designs and manufactures high voltage power supplies. It serves X-ray, laser, e-beam, electrostatic, instrumentation and general-purpose markets. The company was founded in 1960 and is headquartered in Brookfield, CT.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland.

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom.

Impatients N.V. operates an online platform for drug innovations. It provides physicians and patients that are excluded from clinical trials access to drugs in development via early access programs. The company was founded by Ronald Brus, SJaak Vink, Govert J. Schouten, Witt Jan, Erdem Yavuz, and René Beukema in 2012 and is headquartered in Amsterdam, the United Kingdom.

Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022.